Microbiology of airway disease in patients with cystic fibrosis by GILLIGAN, P.
CLINICAL MICROBIOLOGY REVIEWS, Jan. 1991, p. 35-51 Vol. 4, No. 1
0893-8512/91/010035-17$02.00/0
Copyright © 1991, American Society for Microbiology
Microbiology of Airway Disease in Patients with Cystic Fibrosist
PETER H. GILLIGAN
Department of Microbiology-Immunology and Pathology, University of North Carolina School of Medicine, and Clinical
Microbiology-Immunology Laboratories, North Carolina Memorial Hospital,* Chapel Hill, North Carolina 27514
INTRODUCTION........................................................................ 35
PATHOGENESIS OF CF ........................................................................ 36
AIRWAY INFECTIONS ........................................................................ 36
IMPORTANT PATHOGENS IN CF LUNG DISEASE ...................................................................36
Staphylococcus aureus ...................................................................... 36
Virulence ........................................................................ 36
Antimicrobial therapy and susceptibility ........................................................................ 37
Antimicrobial prophylaxis ........................................................................ 37
Pseudomonas aeruginosa....................................................................... 37
Virulence ........................................................................ 37
Role of mucoid P. aeruginosa in pathogenesis of CF lung disease ................................................37
Regulation of MEP production ......................................................................... 38
Immunity to mucoid P. aeruginosa ....................................................................... 39
Antimicrobial resistance and susceptibility testing....................................................................39
Pseudomonas cepacia ....................................................................... 40
Prevalence........................................................................ 40
Laboratory detection ........................................................................ 40
Epidemiology ........................................................................ 41
Typing techniques........................................................................ 41
Pathogenic potential ......................................................................... 41
Antimicrobial resistance ........................................................................ 42
Other Bacterial Agents ........................................................................ 42
Haemophilus influenzae ....................................................................... 42
Streptococcus pneumoniae, enterics, and other glucose nonfermenters ..........................................43
Mycobacteria ........................................................................ 43
Unculturable agents ........................................................................ 43
Fungal agents ......................................................................... 44
Viruses ........................................................................ 44
STRATEGIES FOR CULTURE OF RESPIRATORY SECRETIONS FROM CF PATIENTS .................44
Specimen Collection ........................................................................ 44
Quantitative Sputum Cultures ........................................................................ 44
Sputum Liquefaction ........................................................................ 45





The syndrome of cystic fibrosis (CF) of the pancreas was
first described in 1938 by Anderson (3). She described this
syndrome in children who failed to thrive despite frequent
feedings and had "distended abdomens and attacks of diar-
rhea with large, pale, foul smelling stools." Their stools also
were found to have a low percentage of "split fats." The
designation "CF of the pancreas" was derived from the
finding that children who died in the neonatal period had
characteristic histopathologic lesions of the pancreas. Most
children survived the neonatal period, but in Anderson's
series only 8 of 49 patients survived past their second
t This review was written in honor of Leon Croteau. Leon taught
me the importance of optimism and good humor in life despite his
losing battle with cystic fibrosis.
birthday. In the latter patient group, 44 of 49 deaths were a
result of bronchopulmonary infection usually due to Staph-
ylococcus aureus. Two autopsy findings were characteristic
of this disease. First, these patients had infections primarily
in the airways rather than the lung parenchyma. The second
important finding, confirmed by others (3, 60, 171, 210), was
airway luminal plugging by "thick, tenacious, greenish gray,
purulent material" (3).
Anderson's work described the two fundamental patho-
physiologic problems encountered in CF: pancreatic insuffi-
ciency with malnutrition as well as airway infections. Both
are related to the finding that these patients produce ex-
tremely viscous secretions. These secretions lead to autodi-
gestion of the pancreas through blockage of pancreatic ducts
and inability to secrete digestive enzymes. In the conducting
airways the production of these secretions results in chronic
infection due to several types of organisms. This review will
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focus on these microbes and their epidemiology, pathogenic
mechanisms, antimicrobial resistance, and laboratory detec-
tion in this patient population.
PATHOGENESIS OF CF
In her landmark study, Anderson realized that CF was
likely a genetically based disease (3). The development of
CF is now recognized as an autosomal recessive trait found
in approximately 1 in 2,000 Caucasian children (144). The
disease also occurs in Hispanic and black populations but at
a much lower rate. In 1985, the gene thought to be respon-
sible for CF was localized to a specific region on chromo-
some 7 (194, 198, 206). Using the technique of chromosome
walking and jumping, a research team led by Collins, Rior-
dan, and Tsui identified the actual CF gene on chromosome
7 (101, 158, 160). The specific gene product that is defective
(158) is believed to be present in a transmembrane protein
which these investigators have called CF conductance reg-
ulator. In 68% of the CF patients they have studied, a
mutation has been detected in which a phenylalanine residue
is deleted at amino acid position 508 in the CF conductance
regulator (160). The mutation has been designated as Aphe-
508. This deletion is thought to occur in a functionally
important region of the protein and may adversely affect the
regulation of ion transport at the apical surface of epithelial
cells. This mutation is found primarily in patients with severe
disease. Other mutations in this gene have been recognized
but currently have not been as fully characterized. These
uncharacterized mutations can result in either severe or mild
disease. These findings, still in their infancy, are a major step
towards understanding the pathophysiology of CF.
Even before the discovery of the CF gene and its putative
product, investigators had begun to unravel the basic cellular
defect found in CF. Knowles and colleagues (106) demon-
strated that increased sodium absorption occurred across the
respiratory epithelium of patients with CF. This defect was
found to be stably expressed in tissue culture cells, and these
cells have proven to be extremely valuable in further char-
acterizing defects in ion transport (207, 212). Frizzell et al.
(68), Widdicombe et al. (207), and Boucher et al. (20-22)
have shown that there is a defect in the regulation of chloride
ion secretion in CF respiratory epithelium as well. These
observations may explain why patients with CF have com-
paratively dehydrated surface liquid on their respiratory
epithelium (199). It is believed that this dehydration of
respiratory secretions plays an important role in the defec-
tive mucociliary clearance seen in these patients.
Boat and colleagues (16, 36) reported that the proteogly-
cans in the mucus overlying the ciliated epithelium in CF
patients have increased sulfation. These highly charged
molecules may interact with bacteria or bacterial exoprod-
ucts in a manner that contributes to the viscosity of airway
secretions. Together, the dehydrated surface liquid and
increased sulfation of the airway glycocalyx may explain the
development of tenacious secretions seen in the airways of
CF patients. These secretions may provide a suitable envi-
ronment for the growth of selected microbes.
AIRWAY INFECTIONS
The lungs of neonates with CF are histologically normal
(3). However, in her initial report on CF done during the
pre-antimicrobial era, Anderson clearly recognized the im-
portance of airway infections in the abbreviated lifespan
(usually <2 years) of CF patients. It is now recognized (62,
91, 144, 179, 190, 210) that pulmonary dysfunction is respon-
sible for approximately 90% of deaths in CF patients and is
largely a result of chronic airway infection. These chronic
airway infections are characterized by intercurrent acute
exacerbations with fever, weight loss, increased cough,
change in volume, color, or appearance of sputum, increased
respiratory rate, dyspnea, or rales and rhonchi on chest
examination and appearance of new infiltrates on chest
radiograph (131). Progressive deterioration in lung function
as measured by pulmonary function testing is often the result
(107, 127, 210).
A cycle of relative well-being complicated by repeated
episodes of pulmonary dysfunction is common in CF pa-
tients. With each exacerbation, lung function declines, even-
tually leading to pulmonary failure and death. This process
may take many years and, with effective new antimicrobial
therapies, many patients with CF now survive into adult-
hood (127, 179, 210). A small number of patients remain
relatively free of chronic lung infections and associated
pulmonary disease. These patients fare quite well and have
relatively long survival compared with the more typical
individuals with CF who can now expect to live to their third
or fourth decade (100, 127, 179, 210).
IMPORTANT PATHOGENS IN CF LUNG DISEASE
Chronic lung infection in patients with CF is usually
associated with a limited number of organisms. Two bacte-
rial pathogens, S. aureus and Pseudomonas aeruginosa, are
most often recovered from the respiratory tract of chroni-
cally infected CF patients. In a 1986 survey of U.S. CF
centers (100), P. aeruginosa was found in 60% of respiratory
tract cultures, whereas S. aureus was found in 27%. Other
organisms found with some degree of frequency in the
respiratory tract of CF patients include Haemophilus
influenzae, P. cepacia, and other glucose nonfermenters,
including Xanthomonas maltophilia. In addition, the roles of
Legionella pneumophila, Mycobacterium spp., viruses, and
fungi, especially Aspergillus spp., in lung disease of CF
patients are beginning to be more clearly understood.
Staphylococcus aureus
S. aureus was the first organism recognized to cause
chronic lung infections in young CF patients. In the pre-
antibiotic era, lung infection due to this organism was the
leading cause of their mortality (4). It continues to be an
important pulmonary pathogen, especially in CF patients
who are <10 years old (12, 91, 96, 126, 179, 210, 211).
Virulence. The virulence of S. aureus is dependent on two
factors: the ability to adhere to respiratory epithelium and,
once bound, the ability to evade immune clearance. Two
factors, teichoic acid (2) and slime (31), appear to play
significant roles in adherence of S. aureus to respiratory
epithelium in CF patients. How these two factors interact in
this process is not known. Slime, produced by S. aureus, is
biochemically distinct from expolysaccharides produced by
P. aeruginosa. It is a loosely cell-associated, complex
polysaccharide containing sugars, uronic acid, and amino
acids (208).
Once bound, S. aureus produces a variety of virulence
factors. Factors which may allow it to evade immune clear-
ance include leucocidins, which can lyse phagocytic cells,
capsules, and protein A. In addition, the organism produces
a variety of other virulence factors, including hemolysins,
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hyaluronidase, catalase, coagulase, and several exotoxins
(39).
Precisely how S. aureus causes tissue damage in the lungs
of CF patients has not been defined. Autopsy studies done
during the pre-antibiotic era revealed that S. aureus infection
caused significant lung damage which was responsible for
the death of most CF patients (4, 213).
Antimicrobial therapy and susceptibility. Work on the
pathogenesis of S. aureus-associated lung disease in patients
with CF may have been somewhat limited because of the
efficacy of antistaphylococcal therapy. Antistaphylococcal
beta-lactams including nafcillin, oxacillin, and dicloxacillin
have played a major role in controlling S. aureus infections
in this population (12, 127, 182). In Europe, fusidic acid has
also been used successfully to treat S. aureus infections
(182). Long-term prophylaxis with trimethoprim-sulfameth-
oxazole (TMP-SMX), dicloxacillin, tetracyclines, and first-
generation cephalosporins has some efficacy in suppressing
S. aureus (12, 115, 127). Despite intensive antimicrobial
pressure, resistance in S. aureus recovered from the respi-
ratory tree of CF patients is usually limited to penicillin G.
Methicillin-resistant S. aureus (MRSA) strains are infre-
quently recovered from this group of patients. Recently,
Boxerbaum and colleagues (24) reported that, in one CF
center, no MRSA was recovered in 1984 or 1985 but 14 of
212 patients had MRSA in 1986. They also reported that
MRSA did not have a significant impact on the clinical
course of CF patients even though these patients did not
receive antimicrobial agents specifically targeted for the
MRSA. In addition, 10 of 14 CF patients spontaneously lost
the organism, whereas colonization persisted in 4 patients.
This report suggests, and our experience would confirm, that
MRSA is not of concern in the CF population.
Antimicrobial prophylaxis. Two specific problems are as-
sociated with long-term antistaphylococcal prophylaxis.
First, some data suggest that P. aeruginosa colonization or
infection has emerged more rapidly in patients receiving
antistaphylococcal prophylaxis. Unfortunately, these data
are based primarily on clinical impressions and retrospective
analyses (11, 12, 70, 108). One of the few placebo-controlled
trials looking at efficacy of antistaphylococcal prophylaxis
included only 17 patients, 11 of whom were colonized with
P. aeruginosa on entry into the study; therefore, it is difficult
to assess adequately the role of antistaphylococcal therapy
in promoting P. aeruginosa infection in these patients (115).
A placebo-controlled trial sponsored by the Cystic Fibrosis
Foundation is being performed to determine the efficacy of
long-term antistaphylococcal prophylaxis in CF patients.
Second, an example of antimicrobial pressure resulting in
S. aureus resistance has been found in patients receiving
long-term TMP-SMX prophylaxis. Several investigators (75,
95, 172) have noted that TMP-SMX resistance in this situa-
tion is due to the organism's ability to take up thymidine
from its environment rather than synthesize it by a pathway
that is inhibited by TMP-SMX. Strains that can take up
thymidine from their environment are designated as being
thymidine dependent. We found that, among 95 patients with
S. aureus, 20 had thymidine-dependent S. aureus strains
(TDSA) (75). Of 39 patients with S. aureus who had received
TMP-SMX prophylaxis, 20 harbored TDSA. The mean
duration of TMP-SMX therapy in this group was 30.9
months compared with 11.0 months in 19 patients with no
TDSA strains. The clinical significance of TDSA is not
known. It is known that TDSA has abnormal colonial
morphology or does not grow at all on most commonly used
isolation media. However, TDSA has typical colonial mor-
phology on mannitol-salt agar (75). Thus, to ensure consis-
tent recovery of all S. aureus isolates, we recommend that
this medium be used for all respiratory tract specimens from
CF patients.
Pseudomonas aeruginosa
With the advent of effective antistaphylococcal antimicro-
bial therapy, P. aeruginosa emerged as the most important
bacterial pathogen in lung disease of CF patients (10, 25, 62,
91, 96, 108, 126, 179, 190). A unique feature of CF patients
chronically infected with P. aeruginosa is the recovery of an
unusual morphotype from respiratory secretions. This ob-
servation was first made by Doggett et al. (54, 55) and since
has been confirmed by others (10, 25, 62, 91, 96, 108, 126,
179, 190). This morphotype was designated "mucoid" by
Wabha and Darrell, who have described six P. aeruginosa
morphotypes (197). All six morphotypes have been found in
sputum specimens from CF patients (189). For any given
patient early in infection, the classical morphotype appears
to predominate (91, 140, 157, 210). However, mucoid P.
aeruginosa soon becomes the most common morphotype
(81, 140, 144), although other morphotypes may frequently
be recovered concurrently. In two different populations of
CF patients, one in Cleveland, Ohio (189), and the other in
Denmark (90, 91), approximately 80% of P. aeruginosa
isolates were mucoid. In contrast, in a study of non-CF
patients, only 3% of P. aeruginosa respiratory tract isolates
were mucoid (90).
The mucoid morphotype is due to the production of large
amounts of polysaccharide that surround the cell. This
material has been designated by Pier (144) as "mucoid
exopolysaccharide," or MEP. In earlier studies, this mate-
rial was referred to as "slime" by Evans and Linker (61).
Chakrabarty and his co-workers (48) have designated this
material as "mucoidy." The material to which these studies
refer is a polymer composed of acetylated D-mannuronic
acid and L-guluronic acid and is commonly called alginate (8,
9, 43, 66, 67, 134, 161). In this review, Pier's term, MEP, will
be used. Pier et al. (145), using immunochemical techniques,
demonstrated that all strains of P. aeruginosa isolated from
their CF patients produced MEP, even those classified as
nonmucoid morphotypes.
Virulence. P. aeruginosa isolates produce numerous, di-
verse virulence factors including exotoxin A, exoenzyme S,
elastase, alkaline protease, pyoverdin, two types of hemol-
ysins, lipopolysaccharide, pili, and MEP (58, 62, 94, 130,
190). Literature covering these factors is exceedingly broad
and complex. Only selected aspects of this literature can be
reviewed here. Those interested in further reviewing this
topic should consult two excellent volumes on P. aeruginosa
virulence: one edited by Hoiby and colleagues (94), and the
other edited by Doring et al. (58). Because of the ubiquity of
the mucoid phenotype in the lung of older CF patients, the
role of mucoid P. aeruginosa in the pathogenesis of lung
disease will be briefly reviewed.
Role of mucoid P. aeruginosa in pathogenesis of CF lung
disease. The initiating events in the establishment of chronic
lung infection with mucoid P. aeruginosa are not clearly
understood, nor have any long-term longitudinal studies
been done to clarify this issue. Initial colonization of the
airways is usually due to nonmucoid isolates (91, 140, 157,
210). Under some undefined environmental pressure, these
organisms convert to the mucoid phenotype, and it predom-
inates during chronic lung infection in these patients (15, 48,
52, 80, 155, 174). Costerton and colleagues (42, 110) have
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speculated that mucoid P. aeruginosa grows as microcolo-
nies in the lung and that microcolony formation plays an
important role in the pathogenesis of this infection. Micro-
colony formation may be enhanced by proteases locally
produced by P. aeruginosa. Klinger et al. (103) reported that
pseudomonal proteases cause release of mucins from the
respiratory epithelium. Mucins in CF patients are highly
sulfonated (16, 36) and, when combined with MEP in the
presence of calcium ions, form a highly viscous gel (82).
Increased gel formation enhances microcolony formation,
which may lead to even poorer ciliary clearance of these
organisms.
Not only is ciliary clearance of mucoid P. aeruginosa
probably limited, but also the organism may evade phago-
cytosis. MEP has been shown to be antiphagocytic in vitro,
and optimal killing of P. aeruginosa by phagocytes requires
opsonic antibodies (6, 147, 173). Several pieces of evidence
suggest that opsonization of mucoid P. aeruginosa is limited
in vivo, thus enhancing the ability of mucoid P. aeruginosa
to evade immune clearance in the lung.
Several investigators have found that serum from CF
patients inhibits phagocytosis (93, 188). This inhibitory ac-
tivity is believed to be due to specific antipseudomonal
antibodies, primarily of the immunoglobulin G2 (IgG2) class,
which do not bind to receptor on alveolar macrophages and
are thus not opsonic (64). Hoiby and Olling (93) have found
that some CF patients possess antibodies that block serum
bactericidal activity against P. aeruginosa. Since IgG is the
major immunoglobulin and, thus, opsonin in bronchial fluid
(56), it would be reasonable to expect to see these same
effects due to IgG in the lung.
Another observation that may explain the poor opsoniza-
tion of mucoid P. aeruginosa in the CF lung was made by
Fick and colleagues (63, 65). They have shown that
pseudomonal proteases degrade >80% of IgG in bronchial
fluid, resulting in the inhibition of P. aeruginosa killing by
pulmonary macrophages in vitro. Their explanation for this
finding is that degradation of IgG occurs in a manner such
that the Fab portion remains intact. The Fab portion binds to
the organism, but because the Fc portion is absent, binding
to the phagocytic cells and thus opsonization do not occur.
The long-term survival of mucoid P. aeruginosa in the
lung may lead to damage to the lung in two ways. First,
tissue damage due to the in situ production of pseudomonal
virulence factors such as elastase, exoenzyme S, and exo-
toxin A may occur. Second, the immune response to this
chronic infection may be responsible for tissue damage as
well.
CF patients with high levels of circulating immune com-
plexes have poorer lung function than those with lower
levels (153, 161). Bronchial fluids from CF patients infected
with mucoid P. aeruginosa have been shown to contain
immune complexes, and these patients have increased in-
flammatory reactions in the lung (56, 57). It would appear
that the inflammatory response to the presence of immune
complexes in the lung may be responsible, in part, for the
deterioration of lung function seen in these patients.
Besides immune complex-mediated damage to the lung,
Suter and colleagues have demonstrated that there are very
high levels of elastase and protease of phagocytic cell origin
in the lungs of CF patients infected with P. aeruginosa (180,
181). Although antiprotease inhibitors are present in air-
ways, it is thought that the levels of protease released from
the phagocytes are far in excess of the amount that the
inhibitors can inactivate (180, 181). The observation that CF
patients with more advanced airway disease have high levels
of granulocyte elastase activity in their bronchial secretion
than patients with early disease (29, 181) supports this idea.
At autopsy, the lungs of three of three patients showed
altered lung elastin, indicating that proteolytic enzymes of
both phagocytic and bacterial origin may be important
mediators of airway destruction that occurs during chronic
P. aeruginosa lung infection (29).
These data indicate that the immune response to P.
aeruginosa makes a significant contribution to the tissue
damage seen in the lungs of infected CF patients. One of the
treatment strategies under long-term clinical trial is the use
of corticosteroids to prevent or reduce tissue damage in the
lungs due to inflammation. In a small number of CF patients,
Auerbach et al. (5) have shown that prednisone administered
on alternate days reduces morbidity and improves pulmo-
nary function in patients with mild to moderate lung disease.
Prednisone appears to have two beneficial effects. One effect
is the reduction in serum IgG levels, which correlates with
improved lung function and probably reflects decreased
inflammation and immune complex formation in the lung.
Second, corticosteroids may promote morphologic differen-
tiation of nonciliated epithelial cells to ciliated cells, thus
enhancing pulmonary clearance (22). The use of nonsteroidal
anti-inflammatory agents such as ibuprofen is being consid-
ered for study as well.
Regulation of MEP production. Although the mechanism
by which mucoid P. aeruginosa contributes to lung disease
in CF patients is being elucidated, factors involved in the
expression of the mucoid phenotype in the CF lung are only
now beginning to be understood. The conventional wisdom
of pseudomonal infection in CF patients is that initial infec-
tion is with nonmucoid P. aeruginosa and that mucoid
strains emerge and become predominant as the infection
becomes chronic. As mentioned, all P. aeruginosa isolates
recovered from CF patients studied by Pier et al., regardless
of colonial morphotype (145), can produce MEP. Many CF
patients harbor both mucoid and nonmucoid strains concur-
rently. Only recently has the genetic control of the switching
between nonmucoid and mucoid phenotypes begun to be
understood.
Early studies showed that nonmucoid isolates could be
converted to mucoid ones in the presence of carbenicillin,
certain phages, and pyocins (82, 135, 161). Recent work from
Chakrabarty and colleagues has revealed the events that
may lead to conversion of nonmucoid to mucoid strains. In
a series of publications (8, 9, 15, 43-45, 48-52, 73, 133, 156,
162, 201), they have demonstrated that a cluster of genes on
the P. aeruginosa chromosome is responsible for the initial
steps in MEP synthesis. The expression of these genes is
under regulatory control by a gene which they designate
algR (43, 45, 48). Mutations in this gene or in the gene cluster
lead to the loss of the ability to produce MEP. In addition, by
using complementation experiments in which DNA se-
quences are reintroduced into the chromosome at the site of
these mutations, they produced clones that regained the
ability to produce MEP (43-45, 49-51, 73, 162, 201).
Flynn and Ohman (66,67) and MacGeorge et al. (118) have
identified another chromosomal region which also appears to
be involved in regulating the conversion of nonmucoid to
mucoid strains. Flynn and Ohman (66, 67) have designated
this region algST, whereas MacGeorge et al. (118) have
designated it MUC. These regions are found in similar
locations on the P. aeruginosa chromosome. Flynn and
Ohman (67) have suggested that the algS gene controls
expression of the algT gene and that the algT gene product
regulates alginate synthesis. Whether the algT product acts
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directly on the algR gene or directly on the cluster of the
alginate synthetic genes is not known. The precise mecha-
nism for the genetic regulation of alginate synthesis remains
to be elucidated.
It has long been speculated that the CF lung is a unique
biologic environment and that unknown factors in this envi-
ronment lead to the expression of the mucoid phenotype (35,
135). Now that the genetic events necessary for the expres-
sion of this phenotype are beginning to be understood, it will
be possible to design experiments to determine which factors
regulate gene expression. Preliminary experiments have
been reported in which conditions of high osmolarity lead to
increased expression of the algD gene, one of the genes in
the gene cluster responsible for MEP production (15, 48, 52).
Speert et al. (174) used extreme nutritional stress over
extended incubation times (a minimum of 30 days) to attempt
to induce the P. aeruginosa mucoid phenotype. They found
that mucoid variants could be recovered from 20 of 104
(19.2%) nonmucoid isolates exposed to these conditions.
The rate at which mucoid variants arose was similar for
environmental (24.6%), CF (14.3%), and non-CF (12.1%)
clinical isolates. These data suggest that the P. aeruginosa
strains that infect the airways of CF patients are not neces-
sarily unique, but rather the environment of the CF lung
contains factors which stimulate the expression of the mu-
coid phenotype.
Mucoid P. aeruginosa strains have two phenotypic char-
acteristics that differ from classical strains. Mucoid strains
tend to be serum sensitive (86, 140, 163, 164). By the
International Antigenic Typing System, which is based on
the O-polysaccharide component of lipopolysaccharide (28),
mucoid strains are usually polyagglutinable. Classical strains
are serum resistant and usually monoagglutinable (86, 140).
The polyagglutinability is probably due to a lack of or
reduced number of polysaccharide side chains in these
lipopolysaccharides (69, 88, 181). What role these pheno-
typic factors play in the pathogenesis of infection with this
organism is not known.
Immunity to mucoid P. aeruginosa. Some CF patients
survive to adulthood without becoming chronically colo-
nized or infected with mucoid P. aeruginosa. Pier and
colleagues (147) have reported that these patients had "op-
sonophagocytic" antibodies that were specific for MEP.
Colonized patients also had opsonophagocytic antibodies
but they were not specific for MEP. These MEP-specific
antibodies were found in only 1 of 10 noncolonized young
CF patients and not in normal controls. These data suggest
that, if an immune response could be mounted which was
specific for MEP, CF patients would likely be protected from
P. aeruginosa infection. This observation has important
implications for vaccine development against this organism
(146, 147). A vaccine made of a glycine-EDTA extract of P.
aeruginosa whole cells and a heptavalent lipopolysaccharide
pseudomonal vaccine have been developed. Neither proved
to be of value in protecting CF patients against pseudomonal
infection (112, 128, 141). Vaccines designed to elicit op-
sonophagocytic antibodies to MEP may prove to be useful in
protecting against infection with mucoid P. aeruginosa.
Antimicrobial resistance and susceptibility testing. A com-
prehensive discussion of the development of antimicrobial
resistance in P. aeruginosa lung infection is too complex for
this review. However, several points should be made con-
cerning antimicrobial therapy in CF patients. The issue of
whether P. aeruginosa can be eradicated from the lungs of
CF patients by antimicrobial agents is an important one.
When quantitative sputum cultures are done on CF patients
treated with antipseudomonal therapy, the posttreatment
quantity of P. aeruginosa often declines dramatically and, in
some patients, the organism may become undetectable (70,
107, 127, 138, 152, 169). However, in most patients, 1 to 3
months following treatment, the quantity of P. aeruginosa in
sputum returns to pretreatment levels. Whether the reap-
pearance of P. aeruginosa after antimicrobial therapy (as it
almost always does), represents infection with a new strain
or failure to clear the preexisting strain is not known (99).
Until recently, epidemiologic markers used to address this
issue, such as serotyping, phage typing, phenotyping, pyocin
typing, and antibiograms, have been imprecise (27, 149).
Ogle and colleagues (132, 133) have developed a molecular
probe that has allowed for more precise studies of the
epidemiology of P. aeruginosa. Preliminary work with this
probe suggests that genotypes persist during and after anti-
microbial therapy and that more than one genotype can be
present in the lungs at the same time. In addition, genotypes
can also change over time. Longitudinal studies done over
extended periods of time with this technique are needed to
improve our understanding of the epidemiology of infection
with this organism.
Because of relatively poor penetration of a number of
antimicrobial agents into the respiratory tract of CF patients
(14, 113, 179), the antimicrobial concentrations at that site
are often subinhibitory for P. aeruginosa. The effect of these
subinhibitory concentrations on the virulence of P. aerugi-
nosa is beginning to be more clearly understood and may
explain at least one observation made concerning the ef-
ficacy of therapy. Clinical improvement during antimicrobial
therapy is seen in CF patients who have either no reduction
or only a modest reduction in the number of organisms as
measured by quantitative culture. This improvement is often
attributed to adjunctive therapies such as improved hydra-
tion, oxygenation, and lung physiotherapy (70, 109, 120, 131,
157, 179, 199), and these factors clearly are important in the
comprehensive care of the CF patient. However, subinhib-
itory concentration of several antimicrobial agents have
been shown to inhibit the expression of a number of P.
aeruginosa virulence factors in vitro.
Vishwanath et al. (195) showed that subinhibitory concen-
trations of ceftazidime inhibit the binding of mucoid P.
aeruginosa strains to tracheobronchial mucins but tobramy-
cin does not. Geers and Baker (71, 72) found that MEP
production is greatly reduced in the presence of aminogly-
cosides and, as a result, binding to epithelial cells is also
reduced. Their observations appear to conflict with those of
Vishwanath et al. However, comparisons of these two
studies are difficult because adherence was measured by
using two different experimental systems. Geers and Baker
(71, 72) also found that subinhibitory concentrations of
aminoglycosides inhibited exotoxin A and elastase produc-
tion in both broth and organ culture whereas cephalosporins
did not. Grimwood et al. (83) demonstrated that tobramycin
inhibited elastase production in vitro but did not find signif-
icant reduction in exotoxin A production. Subinhibitory
concentrations of ciprofloxacin reduced in vitro production
of exotoxin A, exoenzyme S, and elastase, while ceftazidime
reduced elastase and phospholipase C levels. In a rat model
of pneumonia, both tobramycin and ciprofloxacin inhibited
exoenzyme S and elastase production, whereas ceftazidime
inhibited only exoenzyme S production. Histologic prepara-
tion of lung sections demonstrated much less tissue damage
in animals treated with agents that inhibit elastase produc-
tion. These data support the hypothesis that localized pro-
duction of elastase is an important initiating event in the
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progressive lung disease seen in CF. Clinical improvement in
the presence of subinhibitory concentrations of antimicro-
bial agents may be explained by suppression of virulence
factors that are responsible for the pathogenicity of these
organisms in the lung.
There are two widely different philosophies about per-
forming susceptibility testing of P. aeruginosa isolates.
Multiple morphotypes (as many as six in our experience) of
P. aeruginosa may be recovered in a single sputum speci-
men. One approach is to perform a separate susceptibility
test on each morphotype. An alternative approach is to test
all morphotypes together in one susceptibility assay (122).
Thomassen et al. (189) reported that different morphotypes
from the same patient had different susceptibilities 51% of
the time, but that similar morphotypes gave similar results
>85% of the time. Govan et al. (80) pointed out that
organisms of the same morphotype could have very different
antimicrobial susceptibility patterns and that susceptibility
of the isolates could change rapidly over the course of
antimicrobial therapy. This group advocated testing as many
as 20 "colonial representatives" by using agar dilution
testing, something that clearly is not practical in most
clinical laboratory settings. Testing different morphotypes is
time-consuming and expensive. It remains to be determined
whether the data generated are of value or whether a
technique testing all morphotypes together will give similar
results at less cost. Maybury et al. (122) found that, when
mixed morphotypes were tested, 94% of MIC results were
within ± 1 dilution of the most resistant morphotype when
each morphotype was tested individually for all antibiotics.
These data suggest that testing multiple morphotypes to-
gether is an accurate and inexpensive alternative to testing
each morphotype individually.
Antimicrobial pressure often results in significant changes
in susceptibility of P. aeruginosa to the agent that is being
used therapeutically (18, 77, 139, 142, 167, 168, 202). Several
studies have shown that increases in MICs, some dramatic,
often occur during therapy with a variety of antimicrobial
agents (26, 46, 77, 89, 139, 142, 167, 168, 176). Not surpris-
ingly, it appears that a resistant subpopulation is selected
that can persist in the presence of a specific antimicrobial
agent. Shalit et al. (168), using quantitative culture tech-
niques, found that after 2 weeks of therapy with ciproflox-
acin approximately 60% of patients harbored ciprofloxacin-
resistant P. aeruginosa. Usually only a small percentage
(0.01 to 10%) of the total P. aeruginosa population was
resistant.
Two other points must be considered when examining the
issue of antimicrobial pressure. First, when antimicrobial
therapy is discontinued, populations of P. aeruginosa from
these patients often, but not always, regain susceptibility to
the particular antimicrobial agent used. Second, resistant
organisms that emerge due to antimicrobial pressure may
persist and be spread to other CF patients in the treatment
center (139). It is not clear whether antimicrobial pressure
has any role in this spread or persistence of these organisms,
but it is clear that P. aeruginosa is extremely adaptable to
interactions with various antimicrobial agents and resistant
subpopulations frequently emerge. Therefore, P. aeruginosa
susceptibility must be carefully monitored to assist the
clinician in making appropriate therapeutic choices.
Pseudomonas cepacia
Prevalence. During the early 1980s, P. cepacia emerged as
a pathogen of potential importance in the lung disease of
patients with CF. This organism has been associated with
significant mortality at CF centers in Philadelphia, Pa.;
Cleveland, Ohio; and Toronto, Ontario, Canada (97, 184,
185, 192). At these three centers, as many as 20% of patients,
primarily young adults, were colonized with this organism.
The disease followed one of three clinical courses. In some
CF patients, long-term colonization occurred without ad-
versely affecting lung function. In others, chronic infection
associated with slowly declining lung function was seen.
Finally, in another group of patients, acute fulminant lung
infection, leading to death in weeks to months, was observed
(97, 192).
Because of the apparent devastating nature of this infec-
tion in a subpopulation of CF patients, the Cystic Fibrosis
Foundation has initiated a nationwide study to determine the
magnitude of the problem. Preliminary results (185a) indi-
cate that this organism is not as widely prevalent in most CF
centers as it was in the three centers that first reported it. In
a multicenter study that did not include the Toronto, Cleve-
land, or Philadelphia centers, Welch and colleagues (205)
found the prevalence to vary from 0 to 14% of patients at
seven geographically diverse centers and the overall mean
isolation rate to be 6.1%.
Laboratory detection. One of the difficulties in attempting
to determine the importance of this organism is that, until the
development of selective media for its isolation, P. cepacia,
in all likelihood, was extremely difficult to recover from
respiratory secretions, especially in patients heavily colo-
nized with mucoid P. aeruginosa (74). MacConkey agar was
the standard medium used to attempt to grow this organism.
Recently, two agar media, PC (74) and OFPBL (205), have
been developed for the specific isolation of P. cepacia. In a
laboratory proficiency test exercise done by the Centers for
Disease Control before the launch of the Cystic Fibrosis
Foundation's national survey, only 36 of 115 laboratories
isolated P. cepacia from mock sputum specimens (183). By
using one of the two P. cepacia selective media, 14 of 15
laboratories isolated this organism, whereas only 22 of 100
that used primarily MacConkey agar as their isolation me-
dium were successful. The laboratories that failed the initial
test were asked to repeat it with P. cepacia selective media.
Seventy-five laboratories agreed to participate, and 73 of 75
successfully isolated P. cepacia. In a multicenter study with
725 clinical specimens (205), P. cepacia was isolated from 58
specimens with OFPBL medium and from only 19 specimens
with MacConkey agar. In a different study, PC medium was
compared with MacConkey agar for detection of P. cepacia
from 169 clinical specimens. Of 35 isolates recovered (74), all
35 were found on PC medium, whereas only 21 were
recovered on MacConkey agar. Two factors contribute to
the superiority of PC and OFPBL media: (i) growth of P.
cepacia frequently is obscured by mucoid P. aeruginosa on
MacConkey agar, whereas the growth of P. aeruginosa
isolates is usually inhibited on the two selective media; and
(ii) P. cepacia grows more rapidly on these media than on
MacConkey agar. Colonies have been observed after 24 to
48 h of incubation on PC and OFPBL media in contrast to 72
h for visible colonies on MacConkey agar (74, 205).
PC and OFPBL each have specific advantages and disad-
vantages. PC medium is more complex to prepare and is
selective only, whereas OFPBL is both differential and
selective (74, 205). However PC is more selective than
OFPBL and is more effective in supporting the growth of P.
cepacia (33). In addition, another Pseudomonas sp., P.
gladioli, has been recovered from sputa of CF patients with
OFPBL. This organism resembles P. cepacia on OFPBL
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(205) and has been confused with it. Christenson et al. (38)
evaluated three patients colonized with P. gladioli and found
that the organism did not appear to have a significant role in
their lung disease. In summary, both OFPBL and PC media
are superior for the recovery ofP. cepacia from sputum. The
choice between these two media should be based on individ-
ual laboratory experience.
Epidemiology. Factors that lead to colonization or infec-
tion by P. cepacia are just beginning to be understood.
Tablan and colleagues (184, 185) did retrospective case
control studies at two different CF centers trying to under-
stand the epidemiology of P. cepacia infection in CF pa-
tients. They found that the risk for P. cepacia colonization
or infection was increased by (i) the severity of underlying
pulmonary disease, (ii) having a sibling with CF who was
also colonized, (iii) increasing age, and (iv) hospitalization in
the previous 6 months. In one of the two centers, the use of
aminoglycoside antimicrobial agents was also associated
with increased risk for P. cepacia infection (184). Because
siblings were at increased risk for colonization, person-to-
person transmission was suggested. Thomassen et al. (191)
have reported that colonization or infection rates in their
institution declined when colonized patients were isolated
from noncolonized patients. In the year before isolation
precautions were instituted, the incidence of P. cepacia was
8.2%. After institution of these infection control measures,
the incidence dropped to 1.7%. These data further support
the role of person-to-person spread.
Alternatively, patients may acquire this organism from
other sources in their environment. P. cepacia infections
associated with environmental contamination of disinfec-
tants and distilled water have been well characterized in
non-CF patients (137). Environmental sampling in two CF
centers revealed that the organism was infrequently isolated.
At one center, 3 of 141 cultures were positive. Surface
cultures from all respiratory therapy and pulmonary function
test equipment were negative (87). At the other center, a
positive culture was obtained from equipment used to test
pulmonary function (97), suggesting a possible source. In a
study of 35 patients, this organism was not recovered from
their home aerosol therapy equipment even though 21 pa-
tients using it were colonized with P. cepacia (148). In
contrast, P. aeruginosa was recovered from the respiratory
therapy equipment of 5 of 36 (31 colonized) patients. These
data suggest that this equipment is more likely to be con-
taminated by P. aeruginosa than by P. cepacia. Much more
information is needed before the way in which P. cepacia
enters and spreads through a population of CF patients is
understood.
Typing techniques. One of the difficulties with attempting
to study the epidemiology of infection with P. cepacia is the
paucity of tools available for classifying these isolates.
Serotyping (88), biotyping (78), and bacteriocin typing (82)
have all been described for P. cepacia. In hospital outbreaks
that were probably due to a single source, serotyping was
found to be of value (88). However, in CF patients, 40% of
isolates either agglutinated in multiple typing sera or were
nonagglutinable, suggesting that serotyping is probably of
little value in this population (78). Biotyping schemes have
also been developed. Although simple to do, biotyping is
probably of limited value in epidemiologic studies. Govan et
al. (82) have used bacteriocin typing and production for
strain discrimination. Fifteen of the isolates tested were
obtained from J. Klinger, Rainbow Babies and Childrens
Hospital, Cleveland, Ohio, which is a center with a high
incidence of P. cepacia-infected patients. These isolates
proved to be a bacteriocin type that was uncommonly
recovered at other hospitals. Unfortunately, it was not
reported whether these isolates were from CF patients or
not. The bacteriocin types appeared to be relatively stable
when isolates were frozen at -70°C or kept on minimal
medium at room temperature. This technique is laborious
and depends on the continued production of bacteriocins by
the producer strains.
A technique that may greatly aid in studying the epidemi-
ology of P. cepacia in CF patients is ribotyping. This
technique, used by LiPuma, Stull, and colleagues (114, 177)
depends on rRNA probing of restriction endonuclease di-
gests of chromosomal DNA of the target organism. In initial
studies (177), they found that the same ribotype persisted
over time in individual patients and that siblings usually had
the same ribotype. Further studies (114) revealed that a
specific ribotype predominated in each of three CF centers
from which isolates were obtained for study. The ribotype of
the predominant strain at each center was different, suggest-
ing that each center had its own "resident" strains. If
ribotyping proves to be a sensitive and specific discriminator
of genotype in P. cepacia, it may be possible, using this
technique, to begin to understand the epidemiology of infec-
tion with this organism.
Pathogenic potential. One of the great paradoxes concern-
ing P. cepacia is whether this organism is a true pathogen or
just a marker of severe lung disease. In the two case-
controlled studies discussed above (184, 185), the patients
who had P. cepacia tended to have much poorer pulmonary
status than those without infection. Several possibilities
exist to explain why P. cepacia infection is associated with
a spectrum of disease from asymptomatic carriage to acute,
fulminant, fatal infection (97, 184, 185). First, P. cepacia
strains may vary significantly in virulence from very low to
extremely high levels. Second, it may act synergistically
with other unidentified agents to cause fulminant infection in
a manner similar to that seen with S. aureus and influenza
virus (32). Third, the severity of P. cepacia infection may be
dependent on tissue damage caused by other organisms.
Severe, preexisting tissue damage may be required before P.
cepacia can initiate a fatal infection. Alternatively, instead
of playing an active role in the patient's lung disease, P.
cepacia may act as a marker for severe irreparable tissue
damage. Whatever the role of P. cepacia in lung disease in
CF patients, the organism is essentially impossible to erad-
icate from the lung, probably due to its resistance to multiple
antimicrobial agents (76, 78, 152, 192). It is not clear whether
P. cepacia plays an active role in tissue destruction, or
whether it colonizes lungs that are so ravaged by infections
by other organisms that this tissue can no longer resist P.
cepacia colonization.
Data are available that would argue that P. cepacia is
nothing more than a colonizer. This organism is essentially
avirulent in animal models when compared with P. aerugi-
nosa. In a guinea pig model of pneumonia, P. cepacia caused
only mild lung disease, while similar concentrations of P.
aeruginosa caused a fulminant fatal pneumonia (78). Gold-
mann and Klinger (78) have shown that P. cepacia can
persist for at least 2 weeks in the rat model of chronic lung
infection described by Cash et al. (34). No animals in their
studies died, although pathologic changes were seen in the
lung. Stover et al. (175), using a burned mouse model of
infection, showed that compared with P. aeruginosa, which
was highly virulent in this model, P. cepacia was avirulent
except at extremely high levels (105 CFU/ml), although it
could persist in cutaneous burn wounds for at least 3 weeks.
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TABLE 1. Virulence factor production of P. cepacia isolates
No. positive/no. tested
Test Gilligan et al. Mckevitt and Woods
(reference 75a) (reference 89)






Esterase lipase (C8) 30/30
a Hydrolysis on Tween 20 agar.
b Hydrolysis on egg yolk agar.
c Determined with the API ZYM test system (Analytab Products, Plain-
view, N.Y.)
Perhaps the data are most consistent with the observation
that patients with severely damaged lungs are colonized but
the organism has only a limited or no role in the progressive
decline in lung function.
Alternatively, P. cepacia strains may vary in virulence,
with certain isolates being highly virulent while others are
essentially avirulent. P. cepacia strains recovered from CF
patients have been studied to determine what virulence
factors the organism might produce. McKevitt and Woods
(125) studied 48 isolates of P. cepacia recovered from CF
patients. They found that most of these isolates degraded
casein and gelatin and were lipolytic (Table 1). Their group
also found that protease purified from a clinical isolate when
instilled in a rat lung could induce bronchopneumonia (124).
However, none of the isolates produced elastase, exoen-
zyme S, or toxin A, all important P. aeruginosa virulence
factors. They also found that culture supernatants had no
activity against three different cell culture lines.
We examined the proteolytic and lipolytic activity of P.
cepacia isolates recovered from CF patients (Table 1) (75a).
Among our isolates, we found rates of proteolytic activity
similar to those seen by McKevitt and Woods (125). We also
found that all isolates had lipolytic activity, although direct
comparison of our data to those of McKevitt and Woods is
not possible because Lonon et al. (117) have reported that
lipase activity of P. cepacia on Tween 20 does not correlate
with activity on egg yolk agar. We also found that P. cepacia
was extremely active against short-chain fatty acids, an
observation that has alse been reported by Poh and Loh
(150). Preliminary studies of purified lipase by Lonon et al.
(117) indicated that this enzyme is not cytotoxic to HeLa
cells nor is it toxic when injected into mice. It is difficult to
reconcile clinical observations which suggest that P. cepacia
is highly virulent, at least in some patients, with in vitro and
animal studies of virulence factors which indicate that P.
cepacia is relatively avirulent. Much more work is needed to
determine the exact role of P. cepacia in lung disease in
patients with CF.
Antimicrobial resistance. Antimicrobial resistance clearly
plays an important role in the ability of P. cepacia to persist
in the lungs of CF patients. The organism is usually resistant
to the aminoglycosides, colistin, carbenicillin, ticarcillin,
and imipenem (77, 97, 152, 192). Although on initial isolation
it is often susceptible to the ureidopenicillins and ceftazi-
dime, the organism possesses an inducible beta-lactamase
(37) and resistance due to derepression of this enzyme may
be a problem posttherapeutically. The quinolones are not
active against P. cepacia at concentrations achievable in
lungs (178, 204), indicating that these antimicrobial agents
will not be useful therapeutically. On initial isolation, many
isolates are susceptible to chloramphenicol and TMP-SMX;
however, resistance to these agents develops during or after
therapy. Some isolates may be resistant to all available
antimicrobial agents, a problem also seen occasionally with
P. aeruginosa. Antimicrobial therapy rarely, if ever, leads to
eradication ofP. cepacia, and this organism has been seen to
emerge during therapy for P. aeruginosa.
A novel approach for treating P. cepacia infection is now
being explored. The studies involve aerosolized amiloride, a
diuretic, that is being used experimentally in the therapy of
adult CF patients (105). The rationale for the use of amiloride
in patients with CF is as follows. One of the major cellular
defects in CF patients is excessive reabsorption of sodium
(Na+) across epithelium cell membranes (106, 199). The
reabsorption of Na+ into airway epithelial cells is accompa-
nied by reabsorption of water from the lung surface liquid,
causing this liquid to become "dehydrated" which may
explain, in part, the viscous secretions seen in CF patients.
Amiloride, when aerosolized into the lung, blocks Na+
reabsorption (199) and, thus, should prevent dehydration,
resulting in less viscous secretions in CF patients. Guinta
and colleagues reported that, in addition to its diuretic effect,
this compound has antimicrobial properties (84). Work by
Cohn and colleagues (40) showed that amiloride and tobra-
mycin act synergistically against P. cepacia at concentra-
tions achievable in the lung by aerosolization. Aerosoliza-
tion of amiloride with tobramycin may prove to be a novel
therapeutic strategy to treat P. cepacia infection.
Other Bacterial Agents
Haemophilus influenzae. During the 1986 survey of CF
centers (100), H. influenzae was recovered from 11% of
cultures done on respiratory secretions of CF patients. H.
influenzae was recovered from 12% of patients at a German
CF center (13) and from 14% at a Danish CF center (91). H.
influenzae is primarily, but not exclusively, found in young
children with CF. The organism is usually nontypable (116),
which is characteristic of the isolates found in patients with
other chronic respiratory diseases. The isolates are most
frequently biotype 1 (116, 203), a trait that has been associ-
ated with enhanced virulence (116). Beta-lactamase-produc-
ing isolates have been found in up to 20% of CF patients
(116, 123, 151). The percentage of isolates that are beta-
lactamase positive varies from center to center, probably
reflecting the known variation found in each geographic
locale (53) rather than any unique feature of H. influenzae
recovered from CF patients. Unlike S. aureus, P. cepacia,
and P. aeruginosa, H. influenzae does not persist for ex-
tended periods of time in the lung (10). Although it has been
associated with pulmonary exacerbations in CF patients
(151), there is no evidence to suggest that it has a primary
role in their chronic progressive pulmonary decline.
Isolation of hemophili from the respiratory secretions of
CF patients can be challenging, especially in patients coin-
fected with mucoid P. aeruginosa. Roberts and Cole (159)
used a hemin-bacitracin medium for isolation of H.
influenzae. One of the key factors for successful isolation
was to incubate the plates anaerobically. Anaerobic incuba-
tion suppressed the growth of P. aeruginosa while allowing
the growth of hemophili. Wong et al. used quantitative
culture techniques and selective agar (209). They found that
H. influenzae was reliably recovered with this method,
although how well this approach compared with qualitative
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cultures was not clear. Bauernfeind et al. (13) used pyocins
to inhibit the growth of P. aeruginosa in order to enhance H.
influenzae recovery. They found that 6 of 17 H. influenzae
isolates would not have been detected if this technique had
not been used. They did not test anaerobic cultures in
parallel; therefore, it is difficult to know whether the added
work necessary to perform cultures with pyocin is of value.
Terpstra et al. (187) have developed a genomic DNA
probe that hybridizes with H. influenzae as well as H.
parainfluenzae, H. parahaemolyticus, and H. haemolyticus.
In situ hybridization studies were positive with seven spu-
tum smears from CF patients, while cultures for H.
influenzae were positive in three of these seven probe-
positive specimens. The authors claimed that "false-nega-
tive" cultures for H. influenzae occurred in the remaining
four specimens. However, an alternative explanation may be
that other hemophili were present, giving rise to a false-
positive hybridization test. Since fairly simple culture tech-
niques exist and the hybridization tests described are labor
intensive, this approach does not seem practical even if the
specificity of the test could be improved.
Streptococcus pneumoniae, enterics, and other glucose non-
fermenters. Streptococcus pneumoniae (92), enteric bacilli
(96, 126), and gram-negative glucose-nonfermenting bacilli
other than P. aeruginosa and P. cepacia (7, 104) are occa-
sionally recovered from the respiratory secretions of CF
patients. Like H. influenzae, none of these organisms seems
to persist for extended periods of time (10, 91). Any role that
they may have in lung disease of these patients is likely to be
secondary to that of the organisms discussed previously.
Mycobacteria. The role of mycobacteria in chronic lung
disease of CF patients has not been extensively studied.
Wood et al. (210) found only two cases of pulmonary
tuberculosis in over 700 CF patients they reviewed. Hoiby
(91) reported that 1.3% of patients at a Danish CF center
were colonized with atypical mycobacteria. Boxerbaum (23)
found that 8 of 430 CF patients were infected with rapidly
growing mycobacteria, six with Mycobacterium chelonei
and two with M. fortuitum. M. chelonei infection was
believed to be the cause of death in one of the six patients.
Smith et al. (170) found that 7 of 223 CF patients were
infected with mycobacteria: three with M. tuberculosis, two
with rapid growers (one each M. fortuitum and M. chelonei),
and two with unidentifiable mycobacteria. Two of three
patients with M. tuberculosis were symptomatic and were
treated successfully; the third, who was asymptomatic, was
not treated. The patient with M. fortuitum died despite
chemotherapy and the organism was recovered from lung
tissue at autopsy. The patient with M. chelonei improved
radiographically and clinically after combination therapy
with rifampin, isoniazid, amikacin, and erythromycin.
Kinney et al. (102) have recently described a case of M.
avium complex infection in an adult CF patient who received
a heart-lung transplant. The lungs removed during transplan-
tation showed extensive granulomas with "caseous necrosis
and liquefaction." The granulomas contained many acid-fast
bacilli. We have found M. avium complex in the sputum
specimens of 12 of 59 adult CF patients. Preliminary studies
suggest that, in one of these patients, this agent was associ-
ated with a decline in lung function (lOla). As life expect-
ancy increases in CF patients, colonization with atypical
mycobacteria may become more prominent. In some, these
organisms may contribute to lung deterioration.
Culturing mycobacteria from sputa of CF patients can be
difficult. CF patients colonized or infected with mycobac-
teria often are also infected with P. aeruginosa. P. aerugi-
nosa can survive decontamination procedures used to elim-
inate other bacterial flora in mycobacterial respiratory tract
cultures. Because of this, they can overgrow the mycobac-
terial cultures as well as degrade and liquefy Lowenstein-
Jensen agar, making mycobacterial isolation impossible
(170). As a result, the importance of direct microscopic
examination of respiratory secretions for acid-fast bacilli
must be emphasized. Although mycobacteria appear to play
a minor role in the lung disease of CF patients, they should
be considered in the differential diagnosis in CF patients with
characteristic symptoms of mycobacterial infection.
Unculturable agents. One of the dilemmas in caring for CF
patients is trying to determine the cause of pulmonary
exacerbation when no obvious changes have occurred in the
type and number of organisms present in their respiratory
secretions. This is a particular problem in patients who have
long-term colonization or infection with mucoid P. aerugi-
nosa. One of the hypotheses to explain this finding is that the
exacerbation is due to some unculturable agent. The obser-
vation that antimicrobial therapy with agents that are essen-
tially inactive against P. aeruginosa results in improved
clinical status supports this theory (120). P. aeruginosa
might obscure the growth of those microbial agents against
which this antimicrobial therapy might be effective. Exam-
ples of slowly growing or difficult to isolate organisms
include H. influenzae and P. cepacia, which can play a role
in pulmonary exacerbations in CF patients.
In the early 1980s, data suggested that L. pneumophila
might be another organism that would be extremely difficult
to culture in the presence of P. aeruginosa and might be
responsible for pulmonary exacerbations in this population.
These data, generated by two groups (59, 98), were based on
serologic responses to L. pneumophila antigens as measured
by an indirect fluorescent-antibody test. In one study (59),
titers of >16 were found in 8 of 46 CF patients but only one
patient had a fourfold rise in titer. In the other study (98), 32
of 109 CF patients had antibody titers of >128. These
investigators found that patients with high antibody levels
had more severe pulmonary disease than those with low
titers. Later work by Collins et al. (41) showed that P.
aeruginosa shares several common antigens with L. pneu-
mophila. Tenover et al. (186) showed that polyclonal anti-
bodies against L. pneumophila cross-react with several
Pseudomonas species, including P. aeruginosa. These data
suggest that the antibody titers seen in CF patients may
represent cross-reactions with Pseudomonas sp. or perhaps
other organisms that colonize the respiratory tree. Gene
probes for Legionella sp. are now widely available. Al-
though false-positive results have been reported with this
technique (111), use of this test may help determine the role
of Legionella spp. in CF lung disease.
Anaerobic bacteria might also play a role in pulmonary
infection of CF patients. Protected bronchial brush speci-
mens, transtracheal aspirates, and lung tissue are optimal
specimens for culture of anaerobes but are seldom obtained.
Consequently, little data are available on the role of anaer-
obes in pulmonary disease of CF patients. Thomassen et al.
(193) studied 17 patients who underwent thoracotomy and
compared tissue or aspirates obtained from that procedure
with sputum cultured quantitatively for both aerobes and
anaerobes. Two of 10 patients studied for the presence of
anaerobes in both sputum and thoractomy specimens had
them in both. In both specimens, P. aeruginosa was present
at levels similar to those of the anaerobes, suggesting that
anaerobes had a secondary role in these infections. Much
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more information is required before the role of anaerobes in
CF patients can be determined.
Fungal agents. The major fungal agent responsible for
pulmonary disease in CF patients is Aspergillus fumigatus.
Specifically, this organism causes allergic bronchopulmo-
nary aspergillosis (ABA). Invasive aspergillosis and as-
pergilloma are unusual in this population (30, 165, 196). The
prevalence of ABA is estimated to be between 0.5 and 11%
in CF patients and is believed to occur primarily in older
children and young adults (30, 121). Generally, disease in CF
patients is sporadic, but a cluster of cases has been described
(121).
The diagnosis of ABA is primarily clinical with the char-
acteristic findings of bronchoconstriction, pulmonary infil-
trates, eosinophilia, increased serum IgE levels, skin test
reactivity, and serum precipitins to A. fumigatus (196). The
recovery of aspergillus from respiratory sqcretions supports
the diagnosis, but it has been estimated that as many as 60 to
80% of CF patients can be colonized with this fungus (196).
Antibodies to A. fumigatus are also common. Surveys of
Aspergillus precipitins (154, 165, 166) have shown that these
antibodies are present in 31 to 37% of CF patients, suggest-
ing that a positive serologic test supports but does not
confirm diagnosis of ABA. Corticosteroids are the treatment
of choice for ABA (30, 196).
Candida albicans frequently can be recovered from the
respiratory tree of CF patients (154), especially those receiv-
ing antimicrobial agents and steroids. However, the role, if
any, that this organism plays in lung disease of these patients
has not been delineated.
Viruses. The role of viruses in the evolution of lung disease
in CF patients has not been determined. It has been postu-
lated that viral respiratory tract infections are important in
predisposing the CF lung to bacterial infection (143, 157). It
is known that ciliary function is normal, at least early in life,
in patients with CF (199). Carson et al. (32) have shown that
viral respiratory tract infections can disrupt ciliary function.
Disruption of ciliary function may then lead to the establish-
ment of secondary bacterial infections and, by a process yet
to be discerned, chronic infection in CF patients. As is seen
in non-CF children (47), viral lower respiratory tract infec-
tions caused by influenza and parainfluenza viruses and
respiratory syncytial virus (RSV) are common in patients
with CF (1, 143, 200). Unfortunately, much of the data that
support this observation are based on serologic rather than
viral culture results.
Wang et al. (200), for example, studied 49 patients with CF
over a 2-year period. During that study, they performed viral
cultures on 1,046 nasal wash specimens, all of which were
negative. Nevertheless, 105 viral infections were detected by
serology, with 40% being asymptomatic. They also found
that CF patients with >1.67 viral infections per year had a
more rapid progression in lung disease than those with fewer
viral infections. Petersen et al. (143), using serologic data
only, suggested that viral infections, especially RSV, were
more common in patients who developed chronic P. aerug-
inosa infection.
The best study to date on the role of viruses in lung disease
in CF patients is by Abman and colleagues (1). Forty-eight
children were studied longitudinally from the time the diag-
nosis of CF was established. Eighteen children were hospi-
talized 30 times for acute respiratory distress. Twelve chil-
dren had a viral pathogen detected, seven of whom had
RSV. Of the seven RSV infections, four were detected by
culture. Of these four, two were also detected by a direct
fluorescent-antibody test for RSV antigens. The remaining
three were diagnosed serologically. The seven patients with
RSV infection had more signs of chronic respiratory disease
and lower radiographic scores than the other CF infants.
These data indicate that viral infections, especially those
caused by RSV, may be responsible, in part, for deteriorat-
ing lung function in young children with CF. Two other
points are relevant in regard to the study by Abman et al.
One is that direct fluorescent-antibody test for RSV, which
has only recently become available, may be of great value in
diagnosing viral respiratory tract infections in CF patients.
Nucleic acid hybridization techniques may also prove useful
for detecting viruses in situ, especially in children colonized
with P. aeruginosa, which readily contaminates cell cultures
used for virus isolation. Second, Abman et al. emphasize the
potential value of antiviral agents in preventing lung damage
due to viral infection which may have long-term conse-
quences in this patient population.
STRATEGIES FOR CULTURE OF RESPIRATORY
SECRETIONS FROM CF PATIENTS
Specimen Collection
The range of microbes that infect the airway of CF
patients presents a challenge for the clinical microbiologist.
In young children with CF, sputum is not produced. As a
result, alternative strategies are used for obtaining material
for culture in this age group. The most commonly used
technique in the young child with CF has been the throat
swab or "gagged" sputum. In this method, a swab is placed
in the pharynx to gag the child. A paroxysm of coughing may
then ensue, resulting in lung secretions being coughed onto
the swab. The flora cultured by this technique may represent
only normal throat flora, but the throat flora in these young
children may reflect the flora in the lung airways. A longitu-
dinal prospective study of lung infection in infants and young
children with CF is being performed at our institution to
begin addressing this issue. In this study, we are comparing
the flora found on throat swabs taken before bronchoscopi-
cally obtained cultures to determine whether upper airway
colonization corresponds to the organisms found in the
lower airways. This study should determine the diagnostic
value of gagged sputum specimens.
In older children and adults, sputum production, espe-
cially during pulmonary exacerbations, is usually copious.
As a result, obtaining sputum that meets criteria for a "good
specimen," i.e., a >1 ratio of white blood cells/epithelial
cells on Gram stain (17, 129), is easily accomplished. Fur-
ther, studies by Thomassen and colleagues (193) have shown
that sputum cultures obtained from CF patients predict the
microflora found in the lung as evidenced by comparing
sputum cultures with culture of lung tissues or aspirates
obtained during thoracotomy. In their study, 15 of 17 pa-
tients had the same organism in sputum and lung tissue or
aspirates. The other two had a positive sputum but negative
aspirate. These data suggest that sputum cultures in older
CF patients generally reflect the flora of the lower airways.
Quantitative Sputum Cultures
Two reasons have been advanced for the use of quantita-
tive sputum cultures. First, it is thought that quantitation of
bacterial numbers is an appropriate means to measure the
efficacy of antimicrobial therapy. This technique, therefore,
has been used in a number of studies (10, 19, 76, 107, 120,
127, 169, 209), especially to measure efficacy of antipseu-
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TABLE 2. Suggested media and incubation conditions for routine culture of respiratory secretions from patients with CF
Medium Incubation conditions Organisms detected
Chocolate/horse blood agar 35-37°C for 3-4 days, ambient air H. influenzae
with bacitracin
or
Horse blood agar 35-37°C for 2-3 days, anaerobically H. influenzae, Streptococcus pneumoniae, S. pyogenes
Mannitol-salt agar 35-37°C for 2-3 days, ambient air Staphylococcus aureus
MacConkey agar 35-37°C for 2-3 days, ambient air P. aeruginosa, other Pseudomonas spp.;
Enterobacteriaceae
PC or OFPBL agar 35-37°C for 3-4 days, ambient air P. cepacia
Sabouraud agar with antibiotics 30 or 35°C for 3-7 days, ambient air Yeasts, molds
domonal therapy. Decline in pseudomonal numbers gener-
ally, but not always, parallelled improved clinical outcomes.
One glaring exception was found in patients with P. cepacia.
Numbers of P. cepacia rarely declined in the face of inten-
sive antipseudomonal therapy despite improvement in clin-
ical condition. In some patients, clinical improvement was
concurrent with decline in P. aeruginosa. In others, how-
ever, P. cepacia was the only potential pathogen present
(76).
The other situation in which quantitative cultures appear
to be of value is in the isolation of selected organisms. Wong
et al. (209) have found that quantitative cultures may be
useful in enhancing the recovery of H. influenzae, especially
in sputum from adult patients. In addition, enhanced recov-
ery of antimicrobial agent-resistant strains of P. aeruginosa
by using quantitative methods has been reported (119).
Sputum Liquefaction
The technique used for quantitation of bacteria in sputum
has varied from study to study. Since CF sputum is highly
viscous, the use of a liquefying agent such as N-acetylcys-
teine or dithiothreitol for liquefaction of sputum has been
important for obtaining reproducible quantitation. Both
agents yielded acceptable results when used with sputum
specimens of patients with CF (85, 209). However, in vitro
studies by Parry and Neu (136) showed that the concentra-
tion of N-acetylcysteine used to liquefy sputum inhibited the
growth of 9 of 13 P. aeruginosa isolates, whereas Hammer-
schlag and colleagues (85) reported that the concentration of
dithiothreitol (50 ,ug/ml) used to liquefy sputum delayed but
did not inhibit the growth of selected strains of H. influenzae
type b, P. aeruginosa, and S. aureus. Mechanical dispersion
of sputum by an electric homogenizer has also been used for
quantitation in clinical studies (77, 80). We recently com-
pared mechanical dispersion versus chemical liquefaction.
Microbial recovery was slightly higher with mechanical than
chemical liquefaction. All results, however, were within 1
log dilution, indicating that either liquefaction strategy is
acceptable as long as it is consistently used (88a).
Strategies for Routine Culturing of Respiratory Secretions
from CF Patients
Sputum or gagged throat swabs are usually cultured qual-
itatively to determine the etiologic agent of acute exacerba-
tions of pulmonary disease in CF patients. The strategy at
our institution is to use different media directed at the
isolation of specific organisms that are associated with these
exacerbations.
For the recovery of S. aureus, the use of mannitol-salt
agar is strongly advocated. Multiresistant P. aeruginosa
strains will not obscure the growth of S. aureus on this
medium as they might on nonselective media or on gram-
positive selective media such as colistin-nalidixic acid agar.
Also, as previously mentioned, mannitol-salt agar readily
supports the growth of thymidine-dependent S. aureus and
enhances the recovery of this organism.
For the recovery of H. influenzae, we use anaerobic
isolation on horse blood agar. This technique has several
advantages: (i) it suppresses the growth of P. aeruginosa
which may obscure the growth of H. influenzae when
isolation is attempted on horse blood agar incubated aerobi-
cally; (ii) hemolytic haemophili can be easily distinguished
from nonhemolytic species on this medium; (iii) both S.
pneumoniae and group A streptococci can be isolated with
this technique, although both are unusual causes of pulmo-
nary exacerbations in CF patients (91, 92, 96).
For isolation of P. aeruginosa and other glucose ferment-
ers and nonfermenters, MacConkey agar is adequate. For
isolation of P. cepacia, PC agar has been reported to be
superior to other commonly available media (74). Alterna-
tively, OFPBL agar can be used for P. cepacia isolation.
Aspergillus sp. and Candida sp. may also play a role in
pulmonary exacerbations and their isolation should be at-
tempted routinely. Sabouraud agar containing chloramphen-
icol and cycloheximide may be used. However, P. aerugi-
nosa may overgrow fungi on this medium. Generally,
incubation for 3 days is sufficient to isolate most common
pathogens, including yeasts and molds, although isolation of
unusual bacteria and fungi may require longer incubation
times. Recommended media and incubation times for isola-
tion of respiratory pathogens from CF patients are summa-
rized in Table 2.
The detection of Legionella sp., Mycobacterium sp., and
viruses present a particular challenge to the clinical micro-
biologist. Attempts to isolate these organisms are often
thwarted by the presence of P. aeruginosa, which can
contaminate viral cultures or overgrow bacterial ones. Be-
cause of this, the development of gene probes and fluores-
cent-antibody reagents for direct detection of these agents is
particularly attractive for diagnosis of respiratory infections
in CF patients.
CONCLUSION
As the effectiveness of antimicrobial therapy for pulmo-
nary exacerbations in CF patients continues to improve, life
expectancy of these patients lengthens. Monitoring the res-
piratory tract flora and understanding its pathogenic poten-
tial will allow the development of new treatment strategies
which may further prolong the lives of these patients.
Understanding of the basic cellular defects in CF should
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allow for the development of novel strategies for prevention
of chronic lung infection in patients with CF.
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